|

cemiplimab+fianlimab Clinical Trials

2 actively recruiting trials across 1 location

▲ +1 trial since July 2026

Pipeline

Phase 2: 2

Top Sponsors

  • University of Chicago1
  • Grupo Español Multidisciplinar de Melanoma1

Indications

  • Cancer2
  • Melanoma and Brain Metastases1
  • Melanoma BRAF V600E/K Mutated1
  • Head and Neck Cancer1

Other1 trial

Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases
Phase 2

Chicago, Illinois1 trial

A Study Comparing Two Immunotherapy Options for Human Papillomavirus Positive HPV-Positive Head and Neck Cancer After Treatment

The University of Chicago

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.